General Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trialBy Healthcare Propulsion StaffSeptember 12, 20260 Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell…
